{"Clinical Trial ID": "NCT01017549", "Intervention": ["INTERVENTION 1:", "Electronic Brachytherapy", "The accelerated partial irradiation of the breasts is the method of administration of radiation therapy that has been commonly used by physicians using Iridium-192 but has been authorized by the FDA prior to commencing registration with an electronic source."], "Eligibility": ["Incorporation criteria:", "Age > 50", "Tumour with Tis, T1, N0, M0 - (Classification AJC)", "* Invasive ductal carcinoma or ductal carcinoma in situ", "- negative surgical microscopic margins of at least 1 mm in all directions", "adequate skin spacing between the surface of the balloon and the surface of the skin - (> 7mm)", "- Exclusion criteria:", "Pregnancy or lactation - (During the treatment part of the study, sexually active women of childbearing age will have to use pregnancy prevention)", "Scleroderma, systemic sclerosis and active lupus", "Infiltrating lobular histology"], "Results": ["Performance measures:", "Number of participants receiving 34 Gy in 10 fractions", "A successful distribution of radioactive treatment defined as a total of 34 Gy in a total of 10 fractions, 3.4 Gy per fraction. (Gray = GY is a measure of the dose of radiation delivered to tissues)", "Duration: measured at the end of the 10th fraction, usually within 7 days", "Results 1:", "Title of the arm/group: Electronic Brachytherapy", "Description of the arm/group: Radiotherapy was administered using the Xoft Axxent detachable system 510(k). Accelerated partial breast irradiation is the method of radiotherapy administration that has been commonly used by physicians using Iridium-192, but the FDA was authorized to use it before commencing registration with an electronic source.", "Total number of participants analysed: 44", "Type of measurement: Number", "Unit of measure: Participants 42"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/44 (0.00 per cent)"]}